Auris Medical will develop betahistine dihydrochloride in a spray formulation for the intranasal treatment of Ménière’s disease and vestibular vertigo. The company also announced last week that it has resumed patient enrollment in the TACTT3 Phase 3 trial of Keyzilen® (AM-101) for acute and post-acute inner ear tinnitus.
This study suggests that not properly treating infections or other conditions that chronically affect the middle ear may lead to neural deficits and increased difficulties hearing in noisy environments.
Usher syndrome is an inherited disorder that reportedly accounts for almost half of all cases of deaf-blindness. There are three types of the disease that are differentiated based on the level of deafness (Type I - innate deafness; Type II - diminished hearing that does not worsen with time, and Type III -progressive decrease in hearing).